Peripheral neuropathy in the COVID-19 era
1Neurology and Clinical Neurophysiology Medical School, University of Cyprus, Nicosia, Cyprus
DOI: 10.22514/sv.2021.189 Vol.17,Issue S1,September 2021 pp.44-44
Submitted: 26 August 2021 Accepted: 06 September 2021
Published: 15 September 2021
The term peripheral neuropathy refers to disorders of the peripheral nervous system (PNS) including single and multiple (asymmetric) mononeuropathies, and symmetrical involvement of many nerves (polyneuropathy). Further classification depends on a mixture of phenomenological, neurophysiological, pathological and aetiological parameters. The temporal evolution of symptoms divides polyneuropathy (PN) into acute or chronic. Acute PN e.g. Guillain-Barré syndrome (GBS) is rare but an important entity to recognise because whilst at times severe, it is treatable. Most PN are chronic and usually develop over several months.
Coronavirus disease 2019 (COVID-19) is a contagious disease caused by SARS-CoV-2. Symptoms of COVID-19 are variable, but often include fever, cough, headache, fatigue, breathing difficulties, and loss of smell or taste. Neurological complications have been reported in the context of COVID-19 infection both in the acute and subacute phase, as part of the post-COVID syndrome or as a result of the vaccination against SARS-CoV-2.
In the acute phase, it has been reported that GBS prevalence is 15 cases per 100,000 SARS-CoV-2 infections. Demyelinating GBSs variant in particular is the most prevalent. Although not necessarily directly caused by SARS-CoV-2, prolonged stay in ICUs is associated with increased risk of ICU related neuro-myopathy. In the chronic phase, preliminary results of ongoing prospective observational studies suggest that patients suffered from COVID-19 have increased risk of developing mild axonal peripheral neuropathy that shows evidence of length dependency.
Interestingly, it has been reported that – even in the absence of electrophysiologically confirmed PN – 1 in 5 patients reported deterioration of pre-existing neuropathic symptoms or development of new neuropathic symptoms, particularly pain, after COVID-19. Such symptoms tend to persist for months.
Further studies are needed to describe the natural history of the PNS involvement during and after COVID-19 infection.
Panagiotis Zis. Peripheral neuropathy in the COVID-19 era. Signa Vitae. 2021. 17(S1);44-44.
Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.
Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.
Chemical Abstracts Service Source Index The CAS Source Index (CASSI) Search Tool is an online resource that can quickly identify or confirm journal titles and abbreviations for publications indexed by CAS since 1907, including serial and non-serial scientific and technical publications.
Index Copernicus The Index Copernicus International (ICI) Journals database’s is an international indexation database of scientific journals. It covered international scientific journals which divided into general information, contents of individual issues, detailed bibliography (references) sections for every publication, as well as full texts of publications in the form of attached files (optional). For now, there are more than 58,000 scientific journals registered at ICI.
Geneva Foundation for Medical Education and Research The Geneva Foundation for Medical Education and Research (GFMER) is a non-profit organization established in 2002 and it works in close collaboration with the World Health Organization (WHO). The overall objectives of the Foundation are to promote and develop health education and research programs.
Scopus: CiteScore 1.0 (2022) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.
Embase Embase (often styled EMBASE for Excerpta Medica dataBASE), produced by Elsevier, is a biomedical and pharmacological database of published literature designed to support information managers and pharmacovigilance in complying with the regulatory requirements of a licensed drug.